Alivus Life Sciences Ltd.
National Stock Exchange of IndiaTotal Valuation
Alivus Life Sciences Ltd. carries a market capitalization of 127.42B, placing it among publicly traded companies globally. Its enterprise value stands at 123.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 127.42B |
| Enterprise Value | 123.26B |
Valuation Ratios
Alivus Life Sciences Ltd. trades at a trailing price-to-earnings ratio of 24.87.
| PE Ratio | 24.87 |
| PS Ratio | 5.14 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Alivus Life Sciences Ltd. trades at an EV/EBITDA multiple of 19.50 and an EV/FCF ratio of 5,006.77. The EV/Sales ratio of 5.14 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.50 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.14 |
| EV / EBITDA | 19.50 |
| EV / EBIT | 19.50 |
| EV / FCF | 5,006.77 |
Financial Position
Alivus Life Sciences Ltd. maintains a current ratio of 9.49, meaning it holds 9.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.64, indicating elevated leverage, while an interest coverage ratio of 190.86 demonstrates strong ability to service its debt obligations.
| Current Ratio | 9.49 |
| Quick Ratio | 2.31 |
| Debt / Equity | 2.64 |
| Debt / EBITDA | N/A |
| Interest Coverage | 190.86 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 1,047.88 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Alivus Life Sciences Ltd. has paid 1.71B in income taxes, reflecting an effective tax rate of 25.67.
| Income Tax | 1.71B |
| Effective Tax Rate | 25.67 |
Stock Price Statistics
Alivus Life Sciences Ltd.'s stock has declined approximately -2.21364% over the past 52 weeks. The 50-day moving average sits at 1,047.86, while the 200-day moving average is 950.69.
| Beta (5Y) | N/A |
| 52-Week Price Change | -2.21364% |
| 50-Day Moving Average | 1,047.86 |
| 200-Day Moving Average | 950.69 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Alivus Life Sciences Ltd. generated 24.00B in revenue and converted that into 4.96B in net income, yielding earnings per share of 40.32. EBITDA reached 6.32B, while operating income came in at 6.32B.
| Revenue | 24.00B |
| Gross Profit | 13.37B |
| Operating Income | 6.32B |
| Pretax Income | 6.67B |
| Net Income | 4.96B |
| EBITDA | 6.32B |
| EBIT | 6.32B |
| Earnings Per Share (EPS) | 40.32 |
Margins
Alivus Life Sciences Ltd. operates with a gross margin of 55.69, reflecting its pricing power and cost economics. The operating margin of 26.34 and net profit margin of 20.65 provide insight into operational efficiency.
| Gross Margin | 55.69 |
| Operating Margin | 26.34 |
| Pretax Margin | 27.79 |
| Profit Margin | 20.65 |
| EBITDA Margin | 26.34 |
Scores
Alivus Life Sciences Ltd. posts an Altman Z-Score of 18.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 18.01 |